PTPA and melanoma: Taken together, these results pinpoint phendione as an inhibitor of PP2A whose effects manifest in increased ATM phosphorylation and activation of the DNA damage response, leading to impaired growth of melanoma cells with acquired resistance to MAPK inhibitors.